180 Life Sciences Stock Today
| ATNF Stock | USD 1.08 0.01 0.93% |
PerformanceVery Weak
| Odds Of DistressVery High
|
180 Life is trading at 1.08 as of the 20th of March 2025. This is a 0.93% increase since the beginning of the trading day. The stock's lowest day price was 1.03. 180 Life has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of June 2017 | Category Healthcare | Classification Health Care |
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company was incorporated in 2016 and is headquartered in Palo Alto, California. The company has 3.18 M outstanding shares of which 25.91 K shares are presently shorted by private and institutional investors with about 0.53 trading days to cover. More on 180 Life Sciences
Moving together with 180 Stock
Moving against 180 Stock
180 Stock Highlights
| CoFounder CoChairman | Sir Feldmann | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt Levels180 Life can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand 180 Life's financial leverage. It provides some insight into what part of 180 Life's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
180 Life Sciences (ATNF) is traded on NASDAQ Exchange in USA. It is located in Building 4, Palo Alto, CA, United States, 94306 and employs 4 people. 180 Life is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.4 M. 180 Life Sciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.18 M outstanding shares of which 25.91 K shares are presently shorted by private and institutional investors with about 0.53 trading days to cover.
180 Life Sciences currently holds about 1.63 M in cash with (10.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04.
Check 180 Life Probability Of Bankruptcy
Ownership Allocation180 Life Sciences owns 18.13 % of its outstanding shares held by insiders and 21.32 % owned by institutions.
Check 180 Ownership Details
180 Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Northern Trust Investments N A | 2024-12-31 | 0.0 | |
| Qube Research & Technologies | 2024-09-30 | 0.0 | |
| Jpmorgan Chase & Co | 2024-09-30 | 0.0 | |
| Virtu Financial Llc | 2024-12-31 | 0.0 | |
| Anson Funds Management Lp | 2024-12-31 | 225.3 K | |
| Hudson Bay Capital Management Lp | 2024-12-31 | 150 K | |
| Rathbone Brothers Plc | 2024-12-31 | 70 K | |
| Ubs Group Ag | 2024-12-31 | 7.2 K | |
| Tower Research Capital Llc | 2024-12-31 | 6.7 K | |
| Blackrock Inc | 2024-12-31 | 564 | |
| Ifp Advisors, Llc | 2024-12-31 | 50.0 |
180 Life Historical Income Statement
180 Stock Against Markets
180 Life Corporate Executives
Elected by the shareholders, the 180 Life's board of directors comprises two types of representatives: 180 Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of 180. The board's role is to monitor 180 Life's management team and ensure that shareholders' interests are well served. 180 Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, 180 Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sir Feldman | CoFounder | Profile | |
| Pr Nanchahal | CoFounder Board | Profile | |
| Pr MD | CoFounder Board | Profile | |
| Ozan CFA | CFO Secretary | Profile |
Already Invested in 180 Life Sciences?
The danger of trading 180 Life Sciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of 180 Life is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than 180 Life. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile 180 Life Sciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether 180 Life Sciences is a strong investment it is important to analyze 180 Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 180 Life's future performance. For an informed investment choice regarding 180 Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in 180 Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 180 Life. If investors know 180 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 180 Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of 180 Life Sciences is measured differently than its book value, which is the value of 180 that is recorded on the company's balance sheet. Investors also form their own opinion of 180 Life's value that differs from its market value or its book value, called intrinsic value, which is 180 Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 180 Life's market value can be influenced by many factors that don't directly affect 180 Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 180 Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if 180 Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 180 Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.